羚锐制药
(600285)
| 流通市值：131.79亿 | | | 总市值：132.08亿 |
| 流通股本：5.66亿 | | | 总股本：5.67亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,020,755,870.55 | 3,500,831,286.92 | 2,759,116,202.14 | 1,906,007,173.3 |
| 营业收入 | 1,020,755,870.55 | 3,500,831,286.92 | 2,759,116,202.14 | 1,906,007,173.3 |
| 二、营业总成本 | 780,335,122.23 | 2,768,148,768.85 | 2,132,955,810.67 | 1,454,748,169.02 |
| 营业成本 | 237,149,305.75 | 846,562,046.44 | 689,715,134.63 | 456,641,718.35 |
| 税金及附加 | 14,102,971.17 | 45,360,022.01 | 35,685,392.76 | 24,859,825.73 |
| 销售费用 | 470,887,517.37 | 1,596,930,049.01 | 1,225,633,298.38 | 854,905,590.92 |
| 管理费用 | 37,493,615.65 | 166,656,502.54 | 120,625,989.94 | 83,629,248.98 |
| 研发费用 | 22,799,572.17 | 131,525,319.54 | 74,489,927.63 | 47,189,927.33 |
| 财务费用 | -2,097,859.88 | -18,885,170.69 | -13,193,932.67 | -12,478,142.29 |
| 其中:利息费用 | 506,504.11 | -767,494.16 | 496,107.52 | 398,322.05 |
| 其中:利息收入 | 2,470,839.15 | 18,824,724.53 | 14,076,809.09 | 12,931,024.37 |
| 加:公允价值变动收益 | -375,621.82 | -10,490.56 | -3,645,807.97 | -2,309,770.4 |
| 加:投资收益 | 12,128,768.89 | 40,214,203.52 | 29,542,544.61 | 17,691,651.56 |
| 资产处置收益 | 411,939.39 | 12,061.9 | 4,611.61 | 2,555.94 |
| 资产减值损失(新) | -4,445.36 | -501,754.11 | -408,905.54 | -473,725.66 |
| 信用减值损失(新) | -2,990,219.63 | -5,719,044.83 | -10,203,400.18 | -3,473,693.7 |
| 其他收益 | 4,092,967.8 | 43,624,190.56 | 21,227,231.58 | 14,020,531.32 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 253,684,137.59 | 810,301,684.55 | 662,676,665.58 | 476,716,553.34 |
| 加:营业外收入 | 56,716.69 | 22,904,745.34 | 3,147,237.32 | 3,019,883.99 |
| 减:营业外支出 | 71,961.72 | 5,633,433.03 | 718,843.85 | 639,786.85 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 253,668,892.56 | 827,572,996.86 | 665,105,059.05 | 479,096,650.48 |
| 减:所得税费用 | 36,935,103.46 | 104,988,304.87 | 91,197,179.05 | 65,981,785.08 |
| 六、净利润 | 216,733,789.1 | 722,584,691.99 | 573,907,880 | 413,114,865.4 |
| 持续经营净利润 | 216,733,789.1 | 722,584,691.99 | 573,907,880 | 413,114,865.4 |
| 归属于母公司股东的净利润 | 216,817,540.12 | 722,550,720.15 | 573,873,093.86 | 413,032,842.54 |
| 少数股东损益 | -83,751.02 | 33,971.84 | 34,786.14 | 82,022.86 |
| (一)基本每股收益 | 0.38 | 1.29 | 1.02 | 0.73 |
| (二)稀释每股收益 | 0.38 | 1.28 | 1.02 | 0.73 |
| 八、其他综合收益 | 6,311,122.23 | -52,945,072.92 | -49,302,213.98 | -56,954,231.11 |
| 归属于母公司股东的其他综合收益 | 6,301,809.7 | -53,020,784.44 | -49,361,808.25 | -56,986,045.3 |
| 九、综合收益总额 | 223,044,911.33 | 669,639,619.07 | 524,605,666.02 | 356,160,634.29 |
| 归属于母公司股东的综合收益总额 | 223,119,349.82 | 669,529,935.71 | 524,511,285.61 | 356,046,797.24 |
| 归属于少数股东的综合收益总额 | -74,438.49 | 109,683.36 | 94,380.41 | 113,837.05 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-30 | 2024-08-13 |
| 审计意见(境内) | | 标准无保留意见 | | |